Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer
Advances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). In non-metastatic NSCLC, adding immune checkpoint inhibitors postchemoradiotherapy has led to improved outcomes in sta...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Academy of Tuberculosis and Respiratory Diseases
2025-07-01
|
| Series: | Tuberculosis and Respiratory Diseases |
| Subjects: | |
| Online Access: | http://e-trd.org/upload/pdf/trd-2024-0159.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849414807258660864 |
|---|---|
| author | Hidenori Kage |
| author_facet | Hidenori Kage |
| author_sort | Hidenori Kage |
| collection | DOAJ |
| description | Advances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). In non-metastatic NSCLC, adding immune checkpoint inhibitors postchemoradiotherapy has led to improved outcomes in stage III disease and during the perioperative period for stages IB–IIIA. Recently, adjuvant osimertinib and alectinib therapy have demonstrated improved survival rates for patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations, respectively; these therapies are now considered standard treatments. Additionally, osimertinib has shown efficacy when administered postchemoradiotherapy in stage III NSCLC. These findings emphasize the importance of assessing EGFR and ALK status to accurately guide treatment decisions for nearly all NSCLC patients, whether they are undergoing curative surgery, chemoradiotherapy, or receiving palliative chemotherapy. This review summarizes recent trials on perioperative and postchemoradiation therapy and advocates for the necessity of molecular testing in non-metastatic NSCLC to enhance patient outcomes. |
| format | Article |
| id | doaj-art-b88fd3efc0454bc2b478e29141f8f7e2 |
| institution | Kabale University |
| issn | 1738-3536 2005-6184 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | The Korean Academy of Tuberculosis and Respiratory Diseases |
| record_format | Article |
| series | Tuberculosis and Respiratory Diseases |
| spelling | doaj-art-b88fd3efc0454bc2b478e29141f8f7e22025-08-20T03:33:42ZengThe Korean Academy of Tuberculosis and Respiratory DiseasesTuberculosis and Respiratory Diseases1738-35362005-61842025-07-0188343144110.4046/trd.2024.01594937Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung CancerHidenori Kage0 Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, JapanAdvances in targeted therapies and immune checkpoint inhibitors have significantly enhanced survival rates for patients diagnosed with metastatic non-small cell lung cancer (NSCLC). In non-metastatic NSCLC, adding immune checkpoint inhibitors postchemoradiotherapy has led to improved outcomes in stage III disease and during the perioperative period for stages IB–IIIA. Recently, adjuvant osimertinib and alectinib therapy have demonstrated improved survival rates for patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) alterations, respectively; these therapies are now considered standard treatments. Additionally, osimertinib has shown efficacy when administered postchemoradiotherapy in stage III NSCLC. These findings emphasize the importance of assessing EGFR and ALK status to accurately guide treatment decisions for nearly all NSCLC patients, whether they are undergoing curative surgery, chemoradiotherapy, or receiving palliative chemotherapy. This review summarizes recent trials on perioperative and postchemoradiation therapy and advocates for the necessity of molecular testing in non-metastatic NSCLC to enhance patient outcomes.http://e-trd.org/upload/pdf/trd-2024-0159.pdfadjuvant therapyimmune checkpoint inhibitorsmolecular testingneoadjuvant therapynon-small cell lung cancertargeted therapy |
| spellingShingle | Hidenori Kage Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer Tuberculosis and Respiratory Diseases adjuvant therapy immune checkpoint inhibitors molecular testing neoadjuvant therapy non-small cell lung cancer targeted therapy |
| title | Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer |
| title_full | Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer |
| title_fullStr | Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer |
| title_full_unstemmed | Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer |
| title_short | Emerging Role of Molecular Testing in the Management of Non-metastatic Non-small Cell Lung Cancer |
| title_sort | emerging role of molecular testing in the management of non metastatic non small cell lung cancer |
| topic | adjuvant therapy immune checkpoint inhibitors molecular testing neoadjuvant therapy non-small cell lung cancer targeted therapy |
| url | http://e-trd.org/upload/pdf/trd-2024-0159.pdf |
| work_keys_str_mv | AT hidenorikage emergingroleofmoleculartestinginthemanagementofnonmetastaticnonsmallcelllungcancer |